Get started

Financials · TEVA

Teva Pharmaceutical Industries Limited (TEVA) financials

For the twelve months ended Sep 30, 2026, Teva Pharmaceutical Industries Limited reported $14.02B of revenue and $506.00M of net income.

Revenue, TTM
$14.02B
Revenue growth, YoY
-16.4%
Net income, TTM
$506.00M
Net income growth, YoY
-28.9%
Net margin
3.6%
Free cash flow, TTM
$1.24B
EPS, diluted, TTM
$0.44
EPS growth, YoY
-26.7%
Cash
$4.08B
P/E
97.77
P/S
3.53
Market cap
$49.47B
Annual revenue$17.26B
FY2016FY2025
Annual net income$1.41B
FY2016FY2025
Annual free cash flow$1.15B
FY2016FY2025

TEVA revenue and earnings growth

TEVA revenueQ3 2026$4.39B

Quarter YoY
-1.9%
QoQ
+6.1%
FY YoY
+4.3%
5Y CAGR
+0.7%
10Y CAGR
-1.3%

TEVA revenue was $4.39B in fiscal Q3 2026 (ended Sep 30, 2026), down 1.9% from a year earlier and up 6.1% from the prior quarter. For the full fiscal 2025 it was $17.26B, up 4.3% from fiscal 2024. Compound annual growth was +0.7% over 5 years and -1.3% over 10 years. It rose in 4 of the last 10 fiscal years.

TEVA net incomeQ3 2026$233.00M

Quarter YoY
-46.2%
10Y CAGR
-1.2%

TEVA net income was $233.00M in fiscal Q3 2026 (ended Sep 30, 2026), down 46.2% from a year earlier. For the full fiscal 2025 it was $1.41B, compared with -$1.64B in fiscal 2024. Compound annual growth was -1.2% over 10 years.

TEVA EPSQ3 2026$0.20

Quarter YoY
-45.9%

TEVA diluted EPS was $0.20 in fiscal Q3 2026 (ended Sep 30, 2026), down 45.9% from a year earlier. For the full fiscal 2025 it was $1.21, compared with -$1.45 in fiscal 2024.

TEVA free cash flowQ3 2026$121.00M

Quarter YoY
-48.1%
QoQ
-60.6%
FY YoY
+53.3%
5Y CAGR
+12.5%
10Y CAGR
-13.3%

TEVA free cash flow was $121.00M in fiscal Q3 2026 (ended Sep 30, 2026), down 48.1% from a year earlier and down 60.6% from the prior quarter. For the full fiscal 2025 it was $1.15B, up 53.3% from fiscal 2024. Compound annual growth was +12.5% over 5 years and -13.3% over 10 years. It rose in 4 of the last 10 fiscal years.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$17.26B$16.54B$15.85B$14.93B$15.88B$16.66B$16.89B$18.27B$21.85B$21.90B
Cost of revenue$8.32B$8.48B$8.20B$7.95B$8.28B$8.93B$9.35B$9.97B$11.24B$10.25B
Gross profit$8.94B$8.06B$7.64B$6.97B$7.59B$7.73B$7.54B$8.30B$10.62B$11.65B
Research and development$1.01B$998.00M$953.00M$838.00M$967.00M$997.00M$1.01B$1.21B$175.00M$422.00M
Selling, general and admin$1.29B$1.16B$1.16B$1.18B$1.10B$1.17B$1.19B$1.30B$1.45B$1.39B
Operating income$2.16B-$303.00M$433.00M-$2.20B$1.72B-$3.57B-$443.00M-$1.64B-$17.48B$2.15B
Interest expense$916.00M$1.00B$1.03B$930.00M$891.00M$901.00M$822.00M$920.00M$875.00M$546.00M
Pre-tax income$1.22B-$1.28B-$624.00M-$3.16B$658.00M-$4.41B-$1.26B-$2.60B-$18.38B$824.00M
Income tax-$180.00M$676.00M-$7.00M-$643.00M$211.00M-$168.00M-$278.00M-$195.00M-$1.93B$521.00M
Net income$1.41B-$1.64B-$559.00M-$2.45B$417.00M-$3.99B-$999.00M-$2.15B-$16.27B$329.00M
EPS, basic$1.23-$1.45-$0.50-$2.20$0.38-$3.64-$0.91-$2.35-$16.26$0.07
EPS, diluted$1.21-$1.45-$0.50-$2.20$0.38-$3.64-$0.91-$2.35-$16.26$0.07
Diluted shares1.16B1.13B1.12B1.11B1.11B1.09B1.09B1.02B1.02B961

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$3.56B$3.30B$3.23B$2.83B$2.20B$2.18B$1.98B$1.78B$963.00M$988.00M
Receivables$3.71B$3.06B$3.41B$3.70B$4.53B$4.58B$5.68B$5.82B$7.13B$7.52B
Inventory$3.18B$3.01B$4.02B$3.83B$3.82B$4.40B$4.42B$4.73B$4.92B$4.95B
Current assets$13.95B$12.55B$12.48B$12.05B$12.57B$13.01B$13.46B$13.79B$15.38B$17.23B
Goodwill$16.00B$16.00B$17.18B$17.18B$17.63B$20.62B$24.85B$24.92B$28.41B$44.41B
Total assets$40.75B$39.33B$43.48B$44.01B$47.67B$50.64B$57.47B$60.68B$70.61B$93.06B
Current liabilities$13.46B$12.80B$12.25B$11.47B$11.03B$13.16B$13.67B$14.32B$17.92B$18.49B
Short-term debt$1.82B$1.78B$1.67B$2.11B$1.43B$3.19B$2.35B$2.22B$3.65B$3.28B
Total debt--------$3.43B$32.52B
Total liabilities$32.83B$33.61B$35.35B$35.41B$36.42B$39.58B$42.41B$44.89B$51.87B$58.06B
Shareholders' equity$7.91B$5.38B$8.13B$8.60B$11.24B$11.06B$15.06B$15.79B$18.75B$34.99B

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow$1.65B$1.25B$1.37B$1.59B$798.00M$1.22B$748.00M$2.45B$2.23B$3.89B
Capital expenditures$501.00M$498.00M$526.00M$548.00M$562.00M$578.00M$525.00M$651.00M$874.00M$901.00M
Free cash flow$1.15B$749.00M$842.00M$1.04B$236.00M$638.00M$223.00M$1.79B$1.35B$2.99B
Investing cash flow$737.00M$792.00M$968.00M$656.00M$1.52B$863.00M$1.35B$1.87B$3.45B-$34.41B
Financing cash flow-$2.15B-$1.79B-$1.91B-$1.49B-$2.17B-$1.89B-$1.93B-$3.35B-$5.75B$25.22B
Dividends paid-------$12.00M$901.00M$1.30B
Share repurchases--------$0$0
Stock-based compensation$157.00M$123.00M$121.00M$124.00M$119.00M$129.00M$119.00M$155.00M$133.00M$124.00M
Depreciation and amortization$1.00B$1.06B$1.15B$1.31B$1.33B$1.56B$1.72B$1.84B$2.11B$1.52B

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY4.3%4.4%6.2%-6.0%-4.7%-1.4%-7.6%-16.4%-0.2%11.5%
Net income growth, YoY----------79.3%
Gross margin51.8%48.7%48.2%46.7%47.8%46.4%44.6%45.4%48.6%53.2%
Operating margin12.5%-1.8%2.7%-14.7%10.8%-21.4%-2.6%-9.0%-80.0%9.8%
Net margin8.2%-9.9%-3.5%-16.4%2.6%-24.0%-5.9%-11.8%-74.4%1.5%
Free cash flow margin6.7%4.5%5.3%7.0%1.5%3.8%1.3%9.8%6.2%13.6%
Return on equity17.8%-30.5%-6.9%-28.4%3.7%-36.1%-6.6%-13.6%-86.8%0.9%
Return on assets3.5%-4.2%-1.3%-5.6%0.9%-7.9%-1.7%-3.5%-23.0%0.4%
Current ratio1.040.981.021.051.140.990.980.960.860.93
Debt to equity--------0.180.93

Source: XBRL data Teva Pharmaceutical Industries Limited files with the SEC, latest filing dated Nov 3, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

TEVA peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
TEVA$14.02B-16.4%$506.00M3.6%$49.47B
VTRS$14.73B+4.3%-$607.80M-4.1%$23.90B
AMRX$3.20B+8.9%$133.30M4.2%$7.45B
PRGO$4.09B-4.5%-$1.77B-43.3%$2.34B

TEVA FAQ

9 questions
  • What is TEVA revenue?
    Teva Pharmaceutical Industries Limited (TEVA) reported $14.02B of revenue for the twelve months ended Sep 30, 2026. That is down 16.4% from the year before. Revenue for fiscal 2025 was $17.26B.
  • Is TEVA profitable?
    Yes. Teva Pharmaceutical Industries Limited earned $506.00M in net income for the twelve months ended Sep 30, 2026, a net margin of 3.6%.
  • How much cash and debt does TEVA have?
    Teva Pharmaceutical Industries Limited reported $4.08B in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is TEVA revenue growing?
    Teva Pharmaceutical Industries Limited's revenue changed +4.3% in fiscal 2025, to $17.26B. Its compound annual growth rate was +0.7% over 5 years and -1.3% over 10 years.
  • What is TEVA gross margin?
    Teva Pharmaceutical Industries Limited's gross profit was $9.22B on $14.02B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 65.8%.
  • What is TEVA free cash flow?
    Teva Pharmaceutical Industries Limited generated $1.24B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $1.77B less capital expenditures.
  • What is TEVA earnings per share?
    Diluted earnings per share were $0.44 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did TEVA last report financial results?
    The latest statements here come from Teva Pharmaceutical Industries Limited's 10-Q filed on Nov 3, 2026, covering the period ended Sep 30, 2026.
  • Where does this TEVA financial data come from?
    Quantisnow builds these statements from the structured XBRL data Teva Pharmaceutical Industries Limited files with the SEC. It is provided for information only and is not investment advice.